Carlsmed (CARL) EBITDA Yield: History & Chart

Basis: Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Source: stored company filings and market data; unavailable inputs remain N/A.

The EBITDA yield is N/A as of 2026-10-06T16:31:28.291Z.

Stored calculation inputs

Calculation as of: 2026-10-06T16:31:28.291Z.

Quote observation: 2026-10-06T16:30:41.000Z. Amounts in USD. The price header may show a later quote.

TTM operating EBITDA · period ending 2026-06-30: -38,256,000
Quote market capitalization: 404,783,652
Total debt · period ending 2026-06-30: 21,917,000
Cash · period ending 2026-06-30: 46,244,000

FMP input reference: 396f74b358d2be52688229160785b883c1ccba5e7e57b4b59ce0869c705c56f9

EV/EBITDA|Earnings Yield|OCF Yield|FCF Yield|All Metrics

CARL EBITDA Yield Metrics

EBITDA YIELD

N/A

CARL Competitors' EBITDA Yield

CARL

Carlsmed, Inc.

Current

Market Cap

$404.78M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

MYGN

Myriad Genetics, Inc.

vs CARL

Market Cap

$410.85M

EBITDA Yield

N/A

TTM Avg

3.45%

3Y Avg

4.91%

5Y Avg

6.50%

NGNE

Neurogene Inc.

vs CARL

Market Cap

$410.80M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

SI

Shoulder Innovations, Inc.

vs CARL

Market Cap

$411.03M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

AVIR

Atea Pharmaceuticals, Inc.

vs CARL

Market Cap

$412.94M

EBITDA Yield

N/A

TTM Avg

951.70%

3Y Avg

394.96%

5Y Avg

394.96%

MPLT

MapLight Therapeutics, Inc.

vs CARL

Market Cap

$396.99M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

EIKN

Eikon Therapeutics, Inc. Common Stock

vs CARL

Market Cap

$414.16M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

PRTA

Prothena Corporation plc

vs CARL

Market Cap

$419.05M

EBITDA Yield

N/A

TTM Avg

6.82%

3Y Avg

6.82%

5Y Avg

6.82%

RGNX

REGENXBIO Inc.

vs CARL

Market Cap

$390.83M

EBITDA Yield

N/A

TTM Avg

13.79%

3Y Avg

13.79%

5Y Avg

8.78%

RZLT

Rezolute, Inc.

vs CARL

Market Cap

$418.87M

EBITDA Yield

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

NAME	MARKET CAP	EBITDA YIELD	TTM	3Y	5Y
Carlsmed, Inc. (CARL)	$404.78M	N/A	N/A	N/A	N/A
Myriad Genetics, Inc. (MYGN)vs ›	$410.85M	N/A	3.45%	4.91%	6.50%
Neurogene Inc. (NGNE)vs ›	$410.80M	N/A	N/A	N/A	N/A
Shoulder Innovations, Inc. (SI)vs ›	$411.03M	N/A	N/A	N/A	N/A
Atea Pharmaceuticals, Inc. (AVIR)vs ›	$412.94M	N/A	951.70%	394.96%	394.96%
MapLight Therapeutics, Inc. (MPLT)vs ›	$396.99M	N/A	N/A	N/A	N/A
Eikon Therapeutics, Inc. Common Stock (EIKN)vs ›	$414.16M	N/A	N/A	N/A	N/A
Prothena Corporation plc (PRTA)vs ›	$419.05M	N/A	6.82%	6.82%	6.82%
REGENXBIO Inc. (RGNX)vs ›	$390.83M	N/A	13.79%	13.79%	8.78%
Rezolute, Inc. (RZLT)vs ›	$418.87M	N/A	N/A	N/A	N/A

EBITDA Yield Formula & Definition

EBITDA Yield = TTM EBITDA / Enterprise Value

EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

EBITDA Yield: N/A

CARL EBITDA Yield Metrics

CARL Competitors' EBITDA Yield

EBITDA Yield Formula & Definition

Related Metrics